AMRX Amneal Pharmaceuticals
$21.12 -1.26%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Point at or drag across the chart to read a day. EOD data.
1D
-1.26%
YTD
+67.60%
P/E
55.65
P/B
140.74
ROE
12.8%
Div yield
—
Beta
0.64
Market cap
$7.4B
RSI (14)
54
Next earnings
Feb 25, 2027
Same sector · Health Care
Compare AMRX with NVO and JNJ →Follow AMRX in the AlfaCat app
Watchlist, price and earnings alerts, the chart offline. Free, no account, no ads.
The economy behind it · United States
Economy this week on BullDozer →GDP, % on year
2.1
Q3 2026
Inflation, %
3.7
Sep 2026
Unemployment, %
3.9
Oct 2026
10-yr yield, %
5.13
Oct 2026
From BullDozer, our sister site for country statistics (open sources: OECD, IMF, Eurostat, ILO). Full United States profile →
Previous session
close of Nov 20, 2026 · EOD, no live order bookOpen
$21.26
Close
$21.12
Day high
$21.71
Day low
$21.07
Volume
1.7M
Latest headlines
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
Yahoo Finance · Nov 19
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease
Yahoo Finance · Nov 19
While Moderna sank 17%, this generic drugmaker quietly jumped 64%
Yahoo Finance · Nov 19
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
Yahoo Finance · Nov 18
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
Yahoo Finance · Nov 18
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
Yahoo Finance · Nov 17
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Nov 9, 2026 View → 8-K Nov 3, 2026 View → 8-K Aug 10, 2026 View → 10-Q Aug 6, 2026 View → 8-K Aug 3, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell AMRX. Try it in the Lab to size a position and see the risk.